Phosphorylated α-synuclein in Parkinson's disease

Yu Wang, Min Shi, Kathryn A. Chung, Cyrus P. Zabetian, James B. Leverenz, Daniela Berg, Karin Srulijes, John Q. Trojanowski, Virginia M.Y. Lee, Andrew D. Siderowf, Howard Hurtig, Irene Litvan, Mya C. Schiess, Elaine R. Peskind, Masami Masuda, Masato Hasegawa, Xiangmin Lin, Catherine Pan, Douglas Galasko, David S. GoldsteinPoul Henning Jensen, Hui Yang, Kevin C. Cain, Jing Zhang

Research output: Contribution to journalArticlepeer-review

215 Scopus citations


Phosphorylated α-synuclein (PS-129), a protein implicated in the pathogenesis of Parkinson's disease (PD), was identified by mass spectrometry in human cerebrospinal fluid (CSF). A highly sensitive and specific assay was established and used to measure PS-129 together with total α-synuclein in the CSF of patients with PD, other parkinsonian disorders such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), and healthy individuals (a total of ~600 samples). PS-129 CSF concentrations correlated weakly with PD severity and, when combined with total a-synuclein concentrations in CSF, contributed to distinguishing PD from MSA and PSP. Further rigorous validation in independent cohorts of patients, especially those where samples have been collected longitudinally, will determine whether the concentration of PS-129 in CSF will be useful for diagnosing PD and for monitoring PD severity and progression.

Original languageEnglish (US)
JournalScience translational medicine
Issue number121
StatePublished - Feb 15 2012

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Phosphorylated α-synuclein in Parkinson's disease'. Together they form a unique fingerprint.

Cite this